Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F22%3A10448292" target="_blank" >RIV/00064203:_____/22:10448292 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/22:10448292
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=XjgOAGHHV_" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=XjgOAGHHV_</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ijid.2022.09.013" target="_blank" >10.1016/j.ijid.2022.09.013</a>
Alternative languages
Result language
angličtina
Original language name
Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?
Original language description
Recently, the recommendations for the treatment of Clostridioides difficile infection (CDI) have been updated. However, in addition to the clinical efficacy data, the drug of choice should ideally represent optimal antimicrobial stewardship, with an emphasis on rapid restoration of the gut microbiota to minimise the risk of infection relapses. Oral administration of metronidazole results in low concentration in stool and interaction with faecal microbiota reduces its antimicrobial bioactivity. Reported elevated minimum inhibitory concentrations of metronidazole in epidemic C. difficile ribotypes and the emergence of plasmid-mediated resistance to metronidazole represent additional potential risks for clinical failure. If metronidazole is the only CDI treatment option, antimicrobial susceptibility testing on agar containing haem should be performed in C. difficile isolate. Compared to metronidazole, oral vancomycin and fidaxomicin reach very high concentrations in the stool, and therefore, have the ability to quickly reduce C. difficile shedding. Healthcare facilities with higher CDI incidence and/or occurrence of epidemic ribotypes should not use metronidazole because prolonged C. difficile shedding can increase the risk for further C. difficile transmission. Only fidaxomicin has a narrow spectrum of antimicrobial activity, which might be together with persistence on spores the main contributing factors to reducing of recurrent CDI rates.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30303 - Infectious Diseases
Result continuities
Project
<a href="/en/project/LX22NPO5103" target="_blank" >LX22NPO5103: National Institute of Virology and Bacteriology</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
International Journal of Infectious Diseases
ISSN
1201-9712
e-ISSN
1878-3511
Volume of the periodical
124
Issue of the periodical within the volume
November
Country of publishing house
GB - UNITED KINGDOM
Number of pages
6
Pages from-to
118-123
UT code for WoS article
000875838200004
EID of the result in the Scopus database
2-s2.0-85139738324